Other medicines, foods and herbal products can change how Zolpidem works. Everything on this page comes from Zolpidem's own FDA-approved label — the same source as the main guide.
Grouped the way the label groups them. Each name links to that medicine's NepalDoc guide; where the label names a class instead of a medicine, the label's words are quoted.
CNS-Active Drugs CNS Depressants Coadministration of zolpidem with other CNS depressants increases the risk of CNS depression. Concomitant use of zolpidem with these drugs may increase drowsiness and psychomotor impairment, including impaired driving ability . Zolpidem tartrate was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs.
Drugs that Affect Drug Metabolism via Cytochrome P450 Some compounds known to induce or inhibit CYP3A may affect exposure to zolpidem. The effect of drugs that induce or inhibit other P450 enzymes on the exposure to zolpidem is not known. CYP3A4 Inducers Rifampin: Rifampin, a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamic effects of zolpidem.
Zolpidem's label names 7 medicines that NepalDoc also covers.
These medicines named in Zolpidem's label have interaction pages of their own:
CNS depressants, including alcohol: Possible adverse additive CNS-depressant effects Opioids: Concomitant use may increase risk of respiratory depression Imipramine: Decreased alertness observed Chlorpromazine: Impaired alertness and psychomotor performance observed CYP3A4 inducers (rifampin or St. John's wort): Combination use may decrease effect Ketoconazole: Combination use may increase effect 7.1 CNS-Active Drugs CNS Depressants Coadministration of zolpidem with other CNS depressants increases the risk of CNS depression. Alcohol An additive adverse effect on psychomotor performance between alcohol and oral zolpidem was demonstrated .
CNS depressants, including alcohol: Possible adverse additive CNS-depressant effects Opioids: Concomitant use may increase risk of respiratory depression Imipramine: Decreased alertness observed Chlorpromazine: Impaired alertness and psychomotor performance observed CYP3A4 inducers (rifampin or St. John's wort): Combination use may decrease effect Ketoconazole: Combination use may increase effect
7.1 CNS-Active Drugs CNS Depressants Coadministration of zolpidem with other CNS depressants increases the risk of CNS depression. Concomitant use of zolpidem with these drugs may increase drowsiness and psychomotor impairment, including impaired driving ability . Zolpidem tartrate was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs. Alcohol An additive adverse effect on psychomotor performance between alcohol and oral zolpidem was demonstrated . Opioids The concomitant use of zolpidem tartrate extended-release tablets with opioids may increase the risk of respiratory depression. Limit dosage and duration of concomitant use of zolpidem tartrate extended-release tablets and opioids . Imipramine, Chlorpromazine Imipramine in combination with zolpidem produced no pharmacokinetic interaction other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zolpidem produced no pharmacokinetic interaction, but there was an additive effect of decreased alertness and psychomotor performance . Sertraline Concomitant administration of zolpidem and sertraline increases exposure to zolpidem . Fluoxetine After multiple doses of zolpidem tartrate and fluoxetine an increase in the zolpidem half-life (17%) was observed. There was no evidence of an additive effect in psychomotor performance . Haloperidol A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem. The lack of a drug interaction following single-dose administration does not predict the absence of an effect following chronic administration .
7.2 Drugs that Affect Drug Metabolism via Cytochrome P450 Some compounds known to induce or inhibit CYP3A may affect exposure to zolpidem. The effect of drugs that induce or inhibit other P450 enzymes on the exposure to zolpidem is not known. CYP3A4 Inducers Rifampin: Rifampin, a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamic effects of zolpidem. Use of Rifampin in combination with zolpidem may decrease the efficacy of zolpidem and is not recommended . St. John's wort: Use of St. John's wort, a CYP3A4 inducer, in combination with zolpidem may decrease blood levels of zolpidem and is not recommended. CYP3A4 Inhibitors Ketoconazole: Ketoconazole, a potent CYP3A4 inhibitor, increased the exposure to and pharmacodynamic effects of zolpidem. Consideration should be given to using a lower dose of zolpidem when a potent CYP3A4 inhibitor and zolpidem are given together .
Zolpidem guide · All interaction pages · Medicines A–Z
This page summarises Zolpidem's FDA-approved label for information — it is not medical advice. Always tell your doctor or pharmacist about every medicine, supplement and herbal product you take.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
Every NepalDoc section, one tap away.
Find doctors by specialty across Nepal.